(NASDAQ: INAB) In8bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.37%.
In8bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast INAB's revenue for 2025 to be $1,291,319,765, with the lowest INAB revenue forecast at $1,291,319,765, and the highest INAB revenue forecast at $1,291,319,765. On average, 1 Wall Street analysts forecast INAB's revenue for 2026 to be $6,690,533,564, with the lowest INAB revenue forecast at $6,690,533,564, and the highest INAB revenue forecast at $6,690,533,564.
In 2027, INAB is forecast to generate $5,426,350,229 in revenue, with the lowest revenue forecast at $5,426,350,229 and the highest revenue forecast at $5,426,350,229.